In a press release, Santhera Pharmaceuticals has announced results from the SYROS study, where long-term treatment with idebenone (also known as Raxone) slowed the decline of forced vital capacity (a test that measures breathing function) over a period of up to 6 years in people living with duchenne musc ular dystrophy. This was supported by other measures of breathing function and idebenone also reduced the risk of bronchopulmonary adverse events and hospitalisations due to respiratory issues.
This long-term data further supports the potential for idebenone to modify the course of respiratory function decline and delay the time to clinically relevant milestones.
“We are very excited to see that the significant treatment effect with idebenone observed in our 52-week Phase III DELOS study is maintained over the long-term,” said Kristina Sjöblom Nygren, MD, Chief Medical Officer and Head of Development at Santhera.
It’s important to note that the SYROS study contained only a small group of people who completed the large phase 3 trial of idebenone in Duchenne (called the DELOS trial) and continued to receive idebenone under Expanded Access Programs (EAPs). However, unlike most clinical trials the SYROS study was a prospectively planned collection of long-term data, so researchers were able to collect real-world data, over a longer period of time than that available to some trials.
Find out more
Contact Neil Bennett, Director of Research, to find out more on 020 7250 8240
More about potential therapies for Duchenne
Raxone: A Guide for the Community
